Author Archive

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Now, a new investigational treatment may help stop these involuntary outbursts…

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology (AAN) Annual Meeting, including a potential new drug for the treatment of multiple sclerosis (MS) and surprising trends showing a reduction in the disease’s severity. The meeting will take place April 10-17 in Toronto…

Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA)…

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada. Dawn McGuire, M.D…

Chronix Biomedical announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS)…

A new study shows that smoking may increase the risk of multiple sclerosis (MS) in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology…

Chronix Biomedical has announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS)…

Researchers have discovered a fifth genetic mutation associated with typical motor neurone disease, or amyotrophic lateral sclerosis, that has a similar pathological effect to certain genetic mutations revealed in earlier studies. Ultimately, the researchers hope that understanding what is causing motor neurone disease (MND) will lead to new avenues for treatment…

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S. The drug, called dalfampridine, is the first therapy for multiple sclerosis that can be taken orally…

A recent US-based study has suggested that doctors may someday be able to predict how likely a patient is to respond well to beta-interferon, by conducting a simple blood test…